Company news
Cellectar Biosciences, Inc. news in 2022
Cellectar Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
November 29, 2022
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference
November 20, 2022
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
November 15, 2022
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
November 2, 2022
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
October 20, 2022
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
September 21, 2022
Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal
September 12, 2022
Cellectar Reports Financial Results for Second Quarter 2022
August 4, 2022
Cellectar Announces Stock Consolidation
July 20, 2022
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
May 9, 2022
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
April 25, 2022
Cellectar Biosciences Announces Key Commercial Team Appointments
April 11, 2022
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
March 20, 2022
Cellectar Biosciences Announces Executive Leadership Changes
February 22, 2022
Decks in 2022
- Investor Presentation (March 2022)
Investor deck · 24 slides · Mar 15, 2022